Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on APL-2302 completing the first phase Ia clinical trial enrollment
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on APL-2302 completing the enrollment of the first phase Ia clinical trial subject
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Annual Performance Report Announcement
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Annual Performance Report Announcement
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on APL-1202 oral administration combined with tiralizumab as a new adjuvant treatment for muscle-invasive bladder cancer released phase II clinical trial data at the 2025 American Society of Clinical Oncology Urogenital Tumors Symposium
CITIC Securities Co., Ltd.\'s inspection opinion on the adjustment of core technical personnel of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the adjustment of core technical personnel
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on opening a special settlement account for cash management of raised funds
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on opening a special settlement account for cash management of raised funds
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Annual Results Pre-loss Announcement
Announcement of Resolutions of the 9th Meeting of the 2nd Board of Supervisors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the use of some temporarily idle funds raised for cash management
CITIC Securities Co., Ltd. inspection opinions on the use of some temporarily idle funds raised by Jiangsu Yahong Pharmaceutical Technology Co., Ltd. for cash management
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (January 10, 2025)
Inspection opinions of CITIC Securities Co., Ltd. on the initial public offering of some restricted shares of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement on the initial public offering of some restricted shares of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the implementation results of share repurchase
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on shareholders\' voluntary commitment to extend the share lockdown period